Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nautilus Biotechnology, Inc. - Common Stock (NQ:NAUT)

1.020 +0.030 (+3.03%)
Streaming Delayed Price Updated: 3:08 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 633,509
Open 1.000
Bid (Size) 1.020 (800)
Ask (Size) 1.030 (3,300)
Prev. Close 0.9900
Today's Range 0.9940 - 1.040
52wk Range 0.6810 - 4.310
Shares Outstanding 124,094,390
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilus... 
From Nautilus Biotechnology Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill

Performance

YTD
-46.6%
-46.6%
1 Month
+14.5%
+14.5%
3 Month
-55.4%
-55.4%
6 Month
-55.5%
-55.5%
1 Year
+44.3%
+44.3%

More News

Read More
Top stock movements in today's session. ↗
Via Chartmill
Which stocks are gapping on Tuesday? ↗
Via Chartmill
Nautilus Biotechnology Inc (NASDAQ:NAUT) Reports Narrower Q4 Loss, Maintains 2027 Cash Runway ↗
Via Chartmill
News headline image
Nautilus Biotechnology Q2 Earnings Call Highlights ↗
Via MarketBeat
Topics Earnings
News headline image
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus (NAUT) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard ↗
Via InvestorPlace
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Q1 Virtual Investor Summit Presentations Now Available On Demand
Via ACCESS Newswire
News headline image
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Investor Summit Announces Q1 Presenter Line Up (Presentations 3/25, 1-on-1s 3/26)
Via ACCESS Newswire
News headline image
Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus (NAUT) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay
From Nautilus Biotechnology Inc.
Via GlobeNewswire
News headline image
Which stocks are moving on Monday? ↗
Via Chartmill

Frequently Asked Questions

Is Nautilus Biotechnology, Inc. - Common Stock publicly traded?
Yes, Nautilus Biotechnology, Inc. - Common Stock is publicly traded.
What exchange does Nautilus Biotechnology, Inc. - Common Stock trade on?
Nautilus Biotechnology, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nautilus Biotechnology, Inc. - Common Stock?
The ticker symbol for Nautilus Biotechnology, Inc. - Common Stock is NAUT on the Nasdaq Stock Market
What is the current price of Nautilus Biotechnology, Inc. - Common Stock?
The current price of Nautilus Biotechnology, Inc. - Common Stock is 1.020
When was Nautilus Biotechnology, Inc. - Common Stock last traded?
The last trade of Nautilus Biotechnology, Inc. - Common Stock was at 09/11/26 03:08 PM ET
What is the market capitalization of Nautilus Biotechnology, Inc. - Common Stock?
The market capitalization of Nautilus Biotechnology, Inc. - Common Stock is 126.58M
How many shares of Nautilus Biotechnology, Inc. - Common Stock are outstanding?
Nautilus Biotechnology, Inc. - Common Stock has 127M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.